Eiger BioPharmaceuticals, Inc. Eiger BioPharmaceuticals, Inc.

Eiger BioPharmaceuticals, Inc.

EIGR

Rangering i aksjer #36453
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company... Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and bringing to market targeted therapies for rare and ultra-rare diseases across the United States and internationally. Its primary investigational drug, Lonafarnib, an orally administered small molecule, is currently undergoing Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection. Other promising candidates in its portfolio include Lambda, which has completed Phase II clinical trials and is designed to target type III interferon receptors; Lonafarnib, also being evaluated for progeria and progeroid laminopathies; and Avexitide, an agent for congenital hyperinsulinism that has also successfully concluded Phase II studies for post-bariatric hypoglycemia. Established in 2008, Eiger BioPharmaceuticals, Inc. maintains its headquarters in Palo Alto, California.
Aksjekurs
$1.73
Sist synkronisert: 2025-06-17
Markedsverdi
$2.55M
Endring (1 dag)
-0.29%
Endring (1 år)
-79.71%
Land
US
Handel Eiger BioPharmaceuticals, Inc. (EIGR)

Kategori

Healthcare
Historikk for aksjesplitt for Eiger BioPharmaceuticals, Inc. (EIGR)
Aksjen Eiger BioPharmaceuticals, Inc. (symbol: EIGR) har gjennomgått totalt 2 aksjesplitt.
Den nyeste splittelsen skjedde Jan 08, 2024.
Én EIGR-aksje kjøpt før Mar 23, 2016 tilsvarer i dag 0.0022222222222222 EIGR-aksjer.
Liste over aksjesplitt
År Splitt Multiplikator Kumulativ multiplikator
2024-01-08 1:30 x0.033333333333333 x0.0022222222222222
2016-03-23 1:15 x0.066666666666667 x0.066666666666667
Aksjesplitt for lignende selskaper eller konkurrenter
Selskap Antall aksjesplitt Kumulativ multiplikator Land
1 x2
US
0 -
US
1 x3
AU
0 -
CH
0 -
NL